Recent advances in natriuretic peptides in congestive heart failure.
Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed.
Boerrigter
Guido
G
Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Burnett
John C
JC
D009320:Atrial Natriuretic Factor / Q000378:metabolism*; D004789:Enzyme Activation; D006162:Guanylate Cyclase / Q000378:metabolism; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism; D009318:Natriuresis / Q000502:physiology; D020097:Natriuretic Peptide, Brain / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use
D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor; D006162:Guanylate Cyclase